肝细胞多倍体在肝脏健康与疾病中的调控
本文综述肝细胞多倍体化的分子机制及其在多种肝病和肝细胞癌中的意义。中心体通过PIDDosome复合物激活p53信号网络限制多倍体化,该通路在肝病中发挥作用。肝细胞多倍体增加是肝脏炎症的标志,可能对肝癌起保护作用,并有望用于风险分层、预后判断和新型治疗策略。
要点
- 肝细胞多倍体增加是肝脏炎症的标志,可能保护 against 肝癌。
- 中心体通过PIDDosome激活p53网络限制肝细胞多倍体化。
- 肝细胞多倍体化机制有望用于肝病风险分层和预后判断。
核心结论
- 肝细胞多倍体化受中心体-PIDDosome-p53通路调控,在肝病中可能具有保护作用。
研究设计与样本
- 本文为综述,讨论肝细胞多倍体化的分子机制及其在肝病和肝细胞癌中的意义。
主要发现
- 肝细胞多倍体增加是肝脏炎症的标志,可能对肝癌起保护作用。
- 中心体通过PIDDosome多蛋白复合物激活p53信号网络限制多倍体化。
关键数值与推荐
- 原文未报告具体数值、阈值或推荐条款。
临床怎么用
- 肝细胞多倍体化理解可能用于肝病和肝细胞癌的风险分层、预后判断及新型治疗策略。
局限性
- 肝细胞多倍体增加对正常生理和多种肝脏病理的影响仍知之甚少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A balanced increase in DNA content (ploidy) is observed in some human cell types, including bone-resorbing osteoclasts, platelet-producing megakaryocytes, cardiomyocytes or hepatocytes. The impact of increased hepatocyte ploidy on normal physiology and diverse liver pathologies is still poorly understood. Recent findings suggest swift genetic adaptation to hepatotoxic stress and the protection from malignant transformation as beneficial effects. Herein, we discuss the molecular mechanisms regulating hepatocyte polyploidisation and its implication for different liver diseases and hepatocellular carcinoma. We report on centrosomes' role in limiting polyploidy by activating the p53 signalling network (via the PIDDosome multiprotein complex) and we discuss the role of this pathway in liver disease. Increased hepatocyte ploidy is a hallmark of hepatic inflammation and may play a protective role against liver cancer. Our evolving understanding of hepatocyte ploidy is discussed from the perspective of its potential clinical application for risk stratification, prognosis, and novel therapeutic strategies in liver disease and hepatocellular carcinoma.
引用
- Sladky VC, Eichin F, Reiberger T, et al. Polyploidy control in hepatic health and disease. J Hepatol. 2021. PMID: 34228992. doi:10.1016/j.jhep.2021.06.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。